secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0000078003-24-000155
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance
---------------------------------------------------------------

- Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.
- Adjusted diluted EPS $0.60, vs $0.67 prior year; includes $1.3B one-time manufacturing optimization costs.
- Raised FY2024 revenue guidance to $59.5-$62.5B (from $58.5-$61.5B) and adjusted EPS to $2.45-$2.65 (from $2.15-$2.35).
- Launched Manufacturing Optimization Program targeting ~$1.5B cost savings by end of 2027; one-time costs ~$1.7B.
- CSO Dr. Mikael Dolsten to depart; successor search underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000155/0000078003-24-000155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800324000155/pfe-20240730.htm
  HTML page:      https://secwatch.observer/filing/0000078003-24-000155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer